系統性壞死治療的全球市場:按藥物類別、疾病類型、給藥途徑、分銷渠道、區域規模、份額、前景、機會分析2021-2028
市場調查報告書
商品編碼
1069125

系統性壞死治療的全球市場:按藥物類別、疾病類型、給藥途徑、分銷渠道、區域規模、份額、前景、機會分析2021-2028

Systemic Scleroderma Treatment Market, by Drug Class, by Disease Type, by Route of Administration, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028

出版日期: | 出版商: Coherent Market Insights | 英文 164 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

硬皮病患病率增加,為開髮用於治療硬皮病的新治療藥物的研發增加,主要市場活躍公司的收購和聯盟,以及其他無機增長戰略 預計招聘的增加將推動市場增長。

本報告調查全球系統性皮膚病治療市場,並提供有關市場前景、市場動態、市場分析、競爭格局等方面的全面信息。

目錄

第 1 章調查目標/先決條件

第二章市場展望

  • 報告說明
    • 市場定義和範圍
  • 執行摘要
    • 市場細分:按藥物類別
    • 市場細分:按疾病類型
    • 市場細分:按管理途徑
    • 市場細分:按分銷渠道
    • 市場細分:按地區
  • 連貫的機會圖 (COM)

第三章市場動態、監管和趨勢分析

  • 市場動態
    • 促進因素
    • 抑制器
    • 市場機會
  • 影響分析
  • 管道分析
  • PEST 分析
  • 監管場景
  • 市場趨勢
  • 主要亮點
  • 兌換場景
  • 併購

第 4 章全球硬皮病治療市場-冠狀病毒 (COVID-19) 大流行的影響

  • 經濟影響
  • 對臨床試驗和藥物開發的影響
  • 政府倡議

第 5 章全球硬皮病治療市場:按藥物類別(100 萬美元)(2017-2028)

  • 簡介
  • 免疫抑製劑
  • 鈣通道阻滯劑
  • 質子泵抑製劑
  • 磷酸二酯□5抑製劑
  • 內皮素受體拮抗劑
  • 前列環素類似物
  • 其他(糖皮質激素、烷化劑、白細胞介素抑製劑等)

第 6 章全球硬皮病治療市場:按疾病類型(100 萬美元)(2017-2028)

  • 簡介
  • 局限性系統性硬化症
  • 瀰漫性系統性硬化症
  • 系統性硬皮病 正餘弦硬皮病

第 7 章全球硬皮病治療市場:按管理途徑(100 萬美元)(2017-2028)

  • 簡介
  • 口語
  • 非腸道

第 8 章全球硬皮病治療市場:按分銷渠道(100 萬美元)(2017-2028)

  • 簡介
  • 醫院藥房
  • 零售藥店
  • 網上藥店

第 9 章全球硬皮病治療市場:區域(100 萬美元)(2017-2028)

  • 簡介
  • 北美
  • 拉丁美洲
  • 歐洲
  • 亞太地區
  • 中東
  • 非洲

第10章競爭態勢

  • 熱圖分析
  • 市場份額分析
    • Bristol-Myers Squibb Company
    • GlaxoSmithKline plc
    • Boehringer Ingelheim International GmbH
    • Corbus Pharmaceuticals
    • Actelion Pharmaceuticals Ltd.
    • Allergan
    • F. Hoffmann-La Roche Ltd.
    • Biogen
    • Novartis AG
    • AstraZeneca
    • Celgene Corporation
    • Ono pharmaceutical co. Ltd.
    • Teva Pharmaceutical Industries Ltd.
    • Aspen Holdings
    • Pfizer Inc.
    • Eli Lilly and Company
    • Bayer AG
    • Amgen Inc.
    • Sanofi
    • Argentis Pharmaceuticals, LLC
  • 分析師觀點

第11章 章節

簡介目錄
Product Code: CMI4641

Scleroderma is a chronic condition which commonly affects the skin and connective tissue. Scleroderma is an autoimmune disorder wherein the immune system of the body produces extra collagen protein which gets deposited in the tissues and causes hardening of skin. Collagen is a fibrous protein which is found abundantly in the body to provide strength and structure to the body. The two major forms of scleroderma include localized and systemic. In localized scleroderma, only the skin is affected and not any organs while in systemic scleroderma, the skin and the underlying tissues under it are affected. Systemic scleroderma affects blood vessels and major organs of the body such as heart, lungs, kidneys, gastrointestinal tract, and others. Systemic scleroderma can be classified into three major types namely, limited systemic sclerosis, diffused systemic sclerosis, and systemic sclerosis sine scleroderma. Limited scleroderma is one of the most common type of systemic scleroderma wherein, the hardening effect of the disease is limited to fingers and it is less likely to cause internal organ damage. In diffused systemic sclerosis, body parts such as fingers, hands, arms, anterior trunk, legs, and face are affected. Diffused systemic sclerosis also affects internal organs such as heart and lungs. In systemic sclerosis sine scleroderma, no skin thickening is seen but internal organs such as heart, kidney, and lungs may get severely damaged.

Market Dynamics

The increasing prevalence of scleroderma, rising research and development activities for the development of novel therapeutics for the treatment of scleroderma, and increasing adoption of inorganic growth strategies such as acquisitions and collaborations by key players operating in the market, are the major factors that are expected to drive growth of the global systemic scleroderma treatment market over the forecast period.

For instance, according to a review article published by the Rheumatology Journal of the British Society for Rheumatology in February 2021, the pooled global prevalence of scleroderma was estimated to be 17.6 per 100,000 people in 2021 and is expected to increase in the near future.

Key features of the study:

  • This report provides in-depth analysis of the global systemic scleroderma treatment market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2021-2028), considering 2020 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global systemic scleroderma treatment market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include Bristol-Myers Squibb Company, GlaxoSmithKline plc, Boehringer Ingelheim International GmbH, Corbus Pharmaceuticals, Actelion Pharmaceuticals Ltd., Allergan, F. Hoffmann-La Roche Ltd., Biogen, Novartis AG, AstraZeneca, Celgene corporation, Ono pharmaceutical co. Ltd., Teva Pharmaceutical Industries Ltd., Aspen Holdings, Pfizer Inc., Eli Lilly and Company, Bayer AG, Amgen Inc., Sanofi, and Argentis Pharmaceuticals, LLC
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global systemic scleroderma treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global systemic scleroderma treatment market

Detailed Segmentation:

  • Global Systemic Scleroderma Treatment Market, By Drug Class:
    • Immunosuppressors
    • Calcium Channel Blockers
    • Proton Pump Inhibitors
    • Phosphodiesterase 5 Inhibitors
    • Endothelin Receptor Antagonists
    • Prostacyclin Analogues
    • Others (Others include Glucocorticoids, Alkylating Agents, and Interleukin Inhibitors)
  • Global Systemic Scleroderma Treatment Market, By Disease Type:
    • Limited Systemic Sclerosis
    • Diffused Systemic Sclerosis
    • Systemic Sclerosis Sine Scleroderma
  • Global Systemic Scleroderma Treatment Market, By Route of Administration:
    • Oral
    • Parenteral
  • Global Systemic Scleroderma Treatment Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Systemic Scleroderma Treatment Market, By Region:
    • North America
      • By Drug Class
      • Immunosuppressors
      • Calcium Channel Blockers
      • Proton Pump Inhibitors
      • Phosphodiesterase 5 Inhibitors
      • Endothelin Receptor Antagonists
      • Prostacyclin Analogues
      • Others (Others include Glucocorticoids, Alkylating Agents, and Interleukin Inhibitors)
      • By Disease Type
      • Limited Systemic Sclerosis
      • Diffused Systemic Sclerosis
      • Systemic Sclerosis Sine Scleroderma
      • By Route of Administration
      • Oral
      • Parenteral
      • By Distribution Channel
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country
      • U.S.
      • Canada
    • Latin America
      • By Drug Class
      • Immunosuppressors
      • Calcium Channel Blockers
      • Proton Pump Inhibitors
      • Phosphodiesterase 5 Inhibitors
      • Endothelin Receptor Antagonists
      • Prostacyclin Analogues
      • Others (Others include Glucocorticoids, Alkylating Agents, and Interleukin Inhibitors)
      • By Disease Type
      • Limited Systemic Sclerosis
      • Diffused Systemic Sclerosis
      • Systemic Sclerosis Sine Scleroderma
      • By Route of Administration
      • Oral
      • Parenteral
      • By Distribution Channel
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
    • Europe
      • By Drug Class
      • Immunosuppressors
      • Calcium Channel Blockers
      • Proton Pump Inhibitors
      • Phosphodiesterase 5 Inhibitors
      • Endothelin Receptor Antagonists
      • Prostacyclin Analogues
      • Others (Others include Glucocorticoids, Alkylating Agents, and Interleukin Inhibitors)
      • By Disease Type
      • Limited Systemic Sclerosis
      • Diffused Systemic Sclerosis
      • Systemic Sclerosis Sine Scleroderma
      • By Route of Administration
      • Oral
      • Parenteral
      • By Distribution Channel
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Russia
      • Rest of Europe
    • Asia Pacific
      • By Drug Class
      • Immunosuppressors
      • Calcium Channel Blockers
      • Proton Pump Inhibitors
      • Phosphodiesterase 5 Inhibitors
      • Endothelin Receptor Antagonists
      • Prostacyclin Analogues
      • Others (Others include Glucocorticoids, Alkylating Agents, and Interleukin Inhibitors)
      • By Disease Type
      • Limited Systemic Sclerosis
      • Diffused Systemic Sclerosis
      • Systemic Sclerosis Sine Scleroderma
      • By Route of Administration
      • Oral
      • Parenteral
      • By Distribution Channel
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
    • Middle East
      • By Drug Class
      • Immunosuppressors
      • Calcium Channel Blockers
      • Proton Pump Inhibitors
      • Phosphodiesterase 5 Inhibitors
      • Endothelin Receptor Antagonists
      • Prostacyclin Analogues
      • Others (Others include Glucocorticoids, Alkylating Agents, and Interleukin Inhibitors)
      • By Disease Type
      • Limited Systemic Sclerosis
      • Diffused Systemic Sclerosis
      • Systemic Sclerosis Sine Scleroderma
      • By Route of Administration
      • Oral
      • Parenteral
      • By Distribution Channel
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country
      • GCC
      • Israel
      • Rest of Middle East
    • Africa
      • By Drug Class
      • Immunosuppressors
      • Calcium Channel Blockers
      • Proton Pump Inhibitors
      • Phosphodiesterase 5 Inhibitors
      • Endothelin Receptor Antagonists
      • Prostacyclin Analogues
      • Others (Others include Glucocorticoids, Alkylating Agents, and Interleukin Inhibitors)
      • By Disease Type
      • Limited Systemic Sclerosis
      • Diffused Systemic Sclerosis
      • Systemic Sclerosis Sine Scleroderma
      • By Route of Administration
      • Oral
      • Parenteral
      • By Distribution Channel
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • By Country/Region
      • South Africa
      • Central Africa
      • North Africa
  • Company Profiles
    • Bristol-Myers Squibb Company*
      • Company Overview
      • Material Portfolio
      • Financial Performance
      • Key Highlights
      • Market Strategies
    • GlaxoSmithKline plc
    • Boehringer Ingelheim International GmbH
    • Corbus Pharmaceuticals
    • Actelion Pharmaceuticals Ltd.
    • Allergan
    • F. Hoffmann-La Roche Ltd.
    • Biogen
    • Novartis AG
    • AstraZeneca
    • Celgene Corporation
    • Ono pharmaceutical co. Ltd.
    • Teva Pharmaceutical Industries Ltd.
    • Aspen Holdings
    • Pfizer Inc.
    • Eli Lilly and Company
    • Bayer AG
    • Amgen Inc.
    • Sanofi
    • Argentis Pharmaceuticals, LLC

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Drug Class
    • Market Snippet, By Disease Type
    • Market Snippet, By Route of Administration
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Pipeline Analysis
  • PEST Analysis
  • Regulatory Scenario
  • Market Trends
  • Key Highlights
  • Reimbursement Scenario
  • Mergers & Acquisitions

4. Global Systemic Scleroderma Treatment Market - Impact of Coronavirus (Covid-19) Pandemic

  • Economic Impact
  • Impact on Clinical Trials and Drug Development
  • Government Initiatives

5. Global Systemic Scleroderma Treatment Market, By Drug Class, 2017 - 2028, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2021 and 2028 (%)
    • Y-o-Y Growth Analysis, 2018 - 2028
    • Segment Trends
  • Immunosuppressors
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • Calcium Channel Blockers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • Proton Pump Inhibitors
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • Phosphodiesterase 5 Inhibitors
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • Endothelin Receptor Antagonists
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • Prostacyclin Analogues
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • Others (Others include Glucocorticoids, Alkylating Agents, and Interleukin Inhibitors)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)

6. Global Systemic Scleroderma Treatment Market, By Disease Type, 2017 - 2028, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2021 and 2028 (%)
    • Y-o-Y Growth Analysis, 2018 - 2028
    • Segment Trends
  • Limited Systemic Sclerosis
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • Diffused Systemic Sclerosis
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • Systemic Sclerosis Sine Scleroderma
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)

7. Global Systemic Scleroderma Treatment Market, By Route of Administration, 2017 - 2028, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2021 and 2028 (%)
    • Y-o-Y Growth Analysis, 2018 - 2028
    • Segment Trends
  • Oral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • Parenteral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)

8. Global Systemic Scleroderma Treatment Market, By Distribution Channel, 2017 - 2028, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2021 and 2028 (%)
    • Y-o-Y Growth Analysis, 2018 - 2028
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)

9. Global Systemic Scleroderma Treatment Market, By Region, 2017 - 2028, (US$ Mn)

  • Introduction
    • Market Share Analysis, By Region, 2021 and 2028 (%)
    • Y-o-Y Growth Analysis, For Regions, 2018-2028
  • North America
    • Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Disease Type, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Route of Administration, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
    • U.S.
    • Canada
  • Latin America
    • Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Disease Type, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Route of Administration, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Disease Type, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Route of Administration, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Disease Type, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Route of Administration, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Disease Type, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Route of Administration, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • Market Size and Forecast, By Drug Class, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Disease Type, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Route of Administration, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Region/Country, 2017 - 2028, (US$ Mn)
    • South Africa
    • Central Africa
    • North Africa

10. Competitive Landscape

  • Heat Map Analysis
  • Market Share Analysis
    • Bristol-Myers Squibb Company
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • GlaxoSmithKline plc
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Boehringer Ingelheim International GmbH
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Corbus Pharmaceuticals
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Actelion Pharmaceuticals Ltd.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Allergan
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • F. Hoffmann-La Roche Ltd.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Biogen
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Novartis AG
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • AstraZeneca
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Celgene Corporation
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Ono pharmaceutical co. Ltd.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Teva Pharmaceutical Industries Ltd.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Aspen Holdings
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Pfizer Inc.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Eli Lilly and Company
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Bayer AG
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Amgen Inc.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Sanofi
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Argentis Pharmaceuticals, LLC
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
  • Analyst Views

11. Section

  • References
  • Research Methodology
  • About us and Sales Contact